AbbVie Inc. Stock
€158.42
Your prediction
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 0.460% | 1.434% | -0.714% | 22.616% | 13.076% | 59.810% | 159.705% |
| Johnson & Johnson | -0.420% | 3.448% | 2.199% | -6.985% | 0.438% | -0.975% | 22.498% |
| Elanco Animal Health Inc. | -0.490% | -7.742% | -30.809% | 7.930% | -13.624% | -61.357% | - |
| Biogen Inc. | -0.290% | -1.327% | -0.668% | -16.318% | -11.705% | -23.945% | 0.096% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, AbbVie Inc., a prominent company in the pharmaceutical industry, appears to be maintaining a strong financial position. The company has demonstrated consistent growth in revenues and net income over the years. However, there are also challenges in certain aspects that could impact the company's financial health.
Revenue growth: From 2020 to 2022, AbbVie's total revenues increased from €45.8 billion to $58.0 billion, signifying a healthy growth rate. This suggests a strong demand for their products and services in the pharmaceuticals industry.
Net income growth: Net income has shown a steady increase. In 2020, the net income stood at €4.6 billion, which rose to €11.5 billion in 2021 and further increased to $11.8 billion in 2022.
Comments
News
3 Absurdly Cheap Stocks to Buy and Hold for Years
Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing
3 Dividend Growth Stocks to Buy and Hold
Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive
3 High-Yield Dividend Stocks That Still Look Like Bargains
The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of